unknown
Stage
1
Investors
About
EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing glasmacinal, an oral non-antibiotic macrolide intended to reduce exacerbations in COPD patients. The candidate is designed to retain macrolide anti-inflammatory and host-defense properties while lacking antibacterial activity to avoid promoting antimicrobial resistance.
Explore EpiEndo Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.